Aggregated News

* FDA to take comments for 60 days before giving final OK

* Critics seek action from Congress, threaten to sue

Dec 21 (Reuters) - A controversial genetically engineered salmon has moved a step closer to the consumer's dining table after the U.S. Food and Drug Administration said Friday the fish didn't appear likely to pose a threat to the environment or to humans who eat it.

AquAdvantage salmon eggs would produce fish with the potential to grow to market size in half the time of conventional salmon. It would be the first food from a transgenic animal - one whose genome has been altered - that has been approved by the FDA.

The AquAdvantage Atlantic salmon egg was developed by AquaBounty Technology, to speed up production to meet global seafood demand.

In a draft environmental assessment Friday, the FDA affirmed earlier findings that the biotech salmon was not likely to be harmful. It said it would take comments from the public on its report for 60 days before making a final decision on approval.

AquaBounty officials said they were...